Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 68, n° 4S1
page AB61 (avril 2013)
Doi : 10.1016/j.jaad.2012.12.256
Clinical Dermatology and Other Cutaneous Disorders

Risk of pruritus in cancer patients treated with inhibitors of the mammalian target of rapamycin, everolimus and temsirolimus: A systematic review of the literature and metaanalysis
 

Courtney Ensslin, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; Alyx Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; Mario Lacouture, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; Shenhong Wu, MD, PhD, Stony Brook University Cancer Center, Stony Brook, NY, United States


 Commercial support: None identified.


Top of the page

© 2013  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@